Ascentage Pharma Group International (AAPG) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 28, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Apr 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AAPG SEC filings page.
Ascentage Pharma Group International (AAPG) reported $71.4M in revenue for fiscal year 2025, down 46.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
AAPG's balance sheet expanded through financing while 2025 revenue contracted and cash losses widened sharply.
The 2025 balance-sheet expansion was financing-led: assets rose58.6% while financing cash flow reached$363M , despite negative operating cash flow. That combination helps explain equity rising427.1% while free cash flow remained-$172M , separating financing supplied from cash generated by operations.
FY2025 revenue fell
The gap between operating cash flow of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Ascentage Pharma Group International's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Ascentage Pharma Group International held $127.7M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $167.9M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Ascentage Pharma Group International scores 30/100 among other emerging companies.
Ascentage Pharma Group International had 373M shares outstanding at the end of fiscal year 2025, against 348M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Ascentage Pharma Group International scores 54/100 among other emerging companies.
Not available for Ascentage Pharma Group International, so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.
Ascentage Pharma Group International reported revenue of $71.4M in fiscal year 2025, against $134.3M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Ascentage Pharma Group International scores 79/100 among other emerging companies.
Ascentage Pharma Group International's operations used $167.9M of cash in fiscal year 2025, against $15.3M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Ascentage Pharma Group International scores 25/100 among other emerging companies.
Ascentage Pharma Group International's cash, cash equivalents and investments came to $127.7M at the end of fiscal year 2025, against $376.0M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Ascentage Pharma Group International scores 37/100 among other emerging companies.
Ascentage Pharma Group International passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.
Ascentage Pharma Group International reported a net loss of $177.7M while operations used $167.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Ascentage Pharma Group International generated $71.4M in revenue in fiscal year 2025. This represents a decrease of 46.9% from the prior year.
Ascentage Pharma Group International reported a net loss of $177.7M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Ascentage Pharma Group International recorded an outflow of $171.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
Ascentage Pharma Group International held $127.7M in cash against $2.1M in long-term debt as of fiscal year 2025, with $235.0M of liabilities due within a year.
Not reported for fiscal year 2025.
Margins & Returns
Ascentage Pharma Group International's ROE was -93.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 60.3 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Ascentage Pharma Group International invested $3.9M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 18.5% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
AAPG Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F |
|---|---|---|---|---|
| Revenue | $71.4M-46.9% | $134.3M+329.7% | $31.3M+2.8% | $30.4M |
| Cost of Revenue | N/A | $4.0M-7.4% | $4.3M+34.9% | $3.2M |
| Gross Profit | N/A | $130.4M+383.5% | $27.0M-0.9% | $27.2M |
| R&D Expenses | N/A | $129.8M+30.3% | $99.6M-7.6% | $107.7M |
| Interest Expense | $160K-16.7% | $192K-55.2% | $429K+1.3% | $424K |
| Income Tax | $992K-30.5% | $1.4Mn/m | -$1.0Mn/m | -$616K |
| Net Income | -$177.7Mn/m | -$55.5Mn/m | -$130.4Mn/m | -$128.0M |
| EPS (Basic) | N/A | -$0.18n/m | -$0.46n/m | -$0.49 |
| EPS (Diluted) | N/A | -$0.18n/m | -$0.46n/m | -$0.49 |
Not reported in any period shown, so not listed: SG&A Expenses, Operating Income, EBITDA, Diluted Shares (Avg).
AAPG Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F |
|---|---|---|---|---|
| Total Assets | $566.8M+58.6% | $357.3M+1.9% | $350.7M | N/A |
| Current Assets | $421.0M+108.5% | $202.0M+6.7% | $189.3M | N/A |
| Cash & Equivalents | $127.7M+4.4% | $122.4M-16.3% | $146.2M-25.1% | $195.1M |
| Short-Term Investments | $0 | N/A | N/A | N/A |
| Inventory | $4.1M+352.8% | $904K-60.3% | $2.3M | N/A |
| Accounts Receivable | $36.2M+217.5% | $11.4M-44.6% | $20.5M | N/A |
| Long-Term Investments | $0 | N/A | N/A | N/A |
| Goodwill | $3.5M+4.4% | $3.4M-2.7% | $3.5M | N/A |
| Total Liabilities | $376.0M+17.1% | $321.1M-6.2% | $342.2M | N/A |
| Current Liabilities | $235.0M+47.0% | $159.8M+21.5% | $131.6M | N/A |
| Non-Current Liabilities | $141.0M-12.6% | $161.3M-23.4% | $210.6M | N/A |
| Long-Term Debt | $2.1M-98.2% | $121.9M-26.6% | $166.1M | N/A |
| Total Equity | $190.8M+427.1% | $36.2M+325.3% | $8.5M-85.6% | $59.2M |
| Retained Earnings | -$120.7M | N/A | N/A | N/A |
AAPG Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F |
|---|---|---|---|---|
| Operating Cash Flow | -$167.9Mn/m | -$15.3Mn/m | -$102.3Mn/m | -$94.8M |
| Capital Expenditures | $3.9M+18.5% | $3.3M-48.8% | $6.5M-78.0% | $29.5M |
| Free Cash Flow | -$171.8Mn/m | -$18.6Mn/m | -$108.8Mn/m | -$124.3M |
| Investing Cash Flow | -$143.0Mn/m | -$49.6M-1706.4% | $3.1Mn/m | -$55.8M |
| Financing Cash Flow | $363.2M+742.3% | $43.1M-17.0% | $51.9M-42.2% | $89.8M |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid, Share Buybacks.
AAPG Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F |
|---|---|---|---|---|
| Gross Margin | N/A | 97.0%+10.8pp | 86.2%-3.3pp | 89.5% |
| Net Margin | -249.0% | -41.3% | -417.0% | -421.0% |
| Return on Equity | -93.2%+60.3pp | -153.5%+1378.6pp | -1532.1%-1316.0pp | -216.0% |
| Return on Assets | -31.4%-15.8pp | -15.6%+21.6pp | -37.2% | N/A |
| Current Ratio | 1.79+0.5x | 1.26-0.2x | 1.44 | N/A |
| Debt-to-Equity | 0.01-3.4x | 3.37-16.2x | 19.52 | N/A |
| Liabilities-to-Equity | 1.97-6.9x | 8.87-31.3x | 40.22 | N/A |
| Asset Turnover | 0.13-0.3x | 0.38+0.3x | 0.09 | N/A |
| FCF Margin | -240.7% | -13.8% | -347.9% | -408.8% |
Not reported in any period shown, so not listed: Operating Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Ascentage Pharma Group International AAPG | FY2025 | $71.4M | -$177.7M | N/A | $1.4B | 45/100 |
| Mirum Pharmaceuticals, Inc. MIRM | FY2025 | $521.3M | -$23.4M | -4.5% | $5.6B | 71/100 |
| Zai Lab Limited ZLAB | FY2025 | $460.2M | -$175.5M | -38.1% | $2.6B | 65/100 |
| Arrowhead Research Corporation ARWR | FY2025 | $829.4M | -$1.6M | -0.2% | $8.3B | 78/100 |
| Acadia Pharmaceuticals Inc. ACAD | FY2025 | $1.1B | $391.0M | 36.5% | $3.5B | 68/100 |
Where Ascentage Pharma Group International Ranks
Frequently Asked Questions
What is Ascentage Pharma Group International's annual revenue?
Ascentage Pharma Group International (AAPG) reported $71.4M in total revenue for fiscal year 2025. This represents a -46.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Ascentage Pharma Group International's revenue growing?
Ascentage Pharma Group International (AAPG) revenue declined by 46.9% year-over-year, from $134.3M to $71.4M in fiscal year 2025.
Is Ascentage Pharma Group International profitable?
No, Ascentage Pharma Group International (AAPG) reported a net loss of $177.7M in fiscal year 2025.
How much debt does Ascentage Pharma Group International have?
As of fiscal year 2025, Ascentage Pharma Group International (AAPG) had $127.7M in cash and equivalents against $2.1M in long-term debt.
What is Ascentage Pharma Group International's return on equity (ROE)?
Ascentage Pharma Group International (AAPG) has a return on equity of -93.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Ascentage Pharma Group International's free cash flow?
Ascentage Pharma Group International (AAPG) recorded an outflow of $171.8M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Ascentage Pharma Group International's operating cash flow?
Ascentage Pharma Group International (AAPG) recorded an outflow of $167.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Ascentage Pharma Group International's total assets?
Ascentage Pharma Group International (AAPG) had $566.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Ascentage Pharma Group International's capital expenditures?
Ascentage Pharma Group International (AAPG) invested $3.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Ascentage Pharma Group International's current ratio?
Ascentage Pharma Group International (AAPG) had a current ratio of 1.79 as of fiscal year 2025, which is generally considered healthy.
What is Ascentage Pharma Group International's debt-to-equity ratio?
Ascentage Pharma Group International (AAPG) had a debt-to-equity ratio of 0.01 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is Ascentage Pharma Group International's liabilities-to-equity ratio?
Ascentage Pharma Group International (AAPG) had a liabilities-to-equity ratio of 1.97 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is Ascentage Pharma Group International's return on assets (ROA)?
Ascentage Pharma Group International (AAPG) had a return on assets of -31.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Ascentage Pharma Group International's P/E ratio?
Ascentage Pharma Group International (AAPG) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $1.4B as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Ascentage Pharma Group International's price-to-sales ratio?
Ascentage Pharma Group International (AAPG) trades at 19.6x sales, its market capitalization divided by $71.4M revenue, FY2025. The market capitalization is $1.4B as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Ascentage Pharma Group International's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Ascentage Pharma Group International (AAPG) held $127.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $167.9M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Ascentage Pharma Group International's Piotroski F-Score?
Ascentage Pharma Group International (AAPG) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ascentage Pharma Group International's earnings high quality?
Ascentage Pharma Group International (AAPG) reported a net loss of $177.7M while operations used $167.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Ascentage Pharma Group International?
Ascentage Pharma Group International (AAPG) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Ascentage Pharma Group International it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.